Kamada (NasdaqGM: KMDA) is a revenue generating biopharmaceutical company that develops and commercializes plasma-derived protein therapeutic products. The Company’s lead product and main revenue driver is Glassia, an alpha-1 antitrypsin (AAT) replacement therapy used to treat AAT deficiency. Glassia revenues have been consistent over the past several years due to a US commercialization agreement with Baxalta, now Shire (NasdaqGS: SHPG), though the Company has indicated a substantial uptick in demand for this product that is expected to increase revenues of their proprietary product line significantly in 2017. Kamada has a robust pipeline greatly based on their AAT therapy, which includes a novel inhaled AAT formulation. The Company also has a steady revenue stream derived from 9 pharmaceutical products and the distribution of 10 products.